anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In 2023, the genetics scientific community celebrated two special anniversaries: the discovery of the double helix structure of DNA was published in 1953 and in 2003 the Human Genome Project was declared completed and made publicly available. To this day, genetics and genomics research is continuing to evolve at high pace and is identifying a steadily increasing number of genes as causal for distinct genetic diseases. The success story of genetics and genomics would not be complete without taking due account of the role of patient advocacy organizations in this process. This paper is based on the personal narrative (oral history) of a father whose daughter was born with a rare genetic disease (RGD) in the 1960s. The first-hand experience of living as a family with an RGD in those days made him a leading pioneer not only in the foundation of patient organizations at national, pan-European, and international levels but also in the development of multi-stakeholder co-operation and networking. Today, patient advocacy organizations play an active role in shaping health and research policies at national, EU, and international levels to ensure that their needs in regard to advancing RGD diagnostics, care, and treatment are addressed.
Burn patients randomly allocated to this group will receive pirfenidone 600 mg orally once per day for 21 days additionally to the coverage of the wound with non-adherent gauzes and bandages. The aforementioned coverings will be changed every 3 or 4 days until a complete re-epithelization is achieved.
WW-binding protein 2 (WBP2) has been demonstrated in different studies to be a tyrosine kinase substrate, to activate ERa/PR transcription and to play a role in breast cancer. However, the role of WBP2 tyrosine phosphorylation in regulating ER function and breast cancer biology is unknown. Here, we established WBP2 as a tyrosine phosphorylation target of estrogen signaling via EGFR crosstalk. Using dominant negative, constitutively active mutants, RNAi and pharmacological studies, we demonstrated that phosphorylation of WBP2 at Tyr192 and Tyr231 could be regulated by c-Src and c-Yes kinases. We further showed that abrogating WBP2 phosphorylation impaired >60% of ERa reporter activity putatively by blocking nuclear entry of WBP2 and its interaction with ERa. Compared to vector control, overexpression of WBP2 and its phospho-mimic mutant in MCF7 resulted in larger tumors in mice, induced loss of cell-cell adhesion, enhanced cell proliferation, anchorage-independent growth, migration and invasion in both estrogen-dependent and-independent manner, events of which could be substantially abolished by overexpression of phosphorylation-defective mutant. Wnt/ss-catenin inhibitor FH535 blocked phospho-WBP2-mediated cancer cell growth more pronouncedly than tamoxifen and fulvestrant, in part by reducing the expression of ERa.
The invention relates to a traditional Chinese medicine composition for treating asthma and trachitis and preparation method. The composition is prepared from rhizoma atractylodis, bighead atractylodes rhizome, rhizoma zingiberis, prepared radix glycyrrhizae, cinnamomum cassia, radix aconiti carmichaeli, perillaseed, semen brassicae and raphani semen based on a appropriate proportion, wherein the rhizoma atractylodis, rhizoma zingiberis, semen brassicae and raphani semen collectively exert functions of warming lung,d removing phlegm and promoting Qi, dispelling cold and dredging collaterals to relieve pain. The bighead atractylodes rhizome, prepared radix glycyrrhizae and perillaseed collectively exert the functions of strengthening spleen and replenishing qi, relieving lung and asthma. The cinnamomum cassia and radix aconiti carmichaeli collectively exert the functions of reinforcing fire to promote Yang and regulating qi to induct harmony. The traditional Chinese medicine composition for treating asthma and trachitis has the functions of ventilating lung qi, resolving sputum and relieving asthma, strengthening spleen and strengthening the essence, can be used for treating asthma, trachitis, coughing and the like, has good treatment effect and low cost, and root out the diseases, and has few side or toxic effect. The preparation of the traditional Chinese medicine composition for treating asthma and trachitis is simple in preparation process. The effective components of all the materials are preserved to the maximum, and the effect of the material is fully exerted.
Embodiments of the present invention provide a composition for a chewable gummy for body tonner. The composition comprises, but not limited to, a predetermined quantity of Green coffee bean extract; a predetermined quantity of Vitamin C; a predetermined quantity of Sodium; and a predetermined quantity of L-carnitine. The chewable gummy of the present invention help in improving metabolism of the body. An increased metabolism results in better digestion and maintain presence of adequate amount of energy on the body. The present invention helps in drastically removing excessive fat by converting it into energy. Furthermore, since the ingredients are nontoxic and do not have any adverse effect on body, the composition is completely safe for consumption. In addition, the gummies make the composition easier and regular to take thereby showing promising positive results in managing weight and body toning.
Described herein are systems for 4D imaging of the lung based on live 2D ultrasound images. An ultrasound probe generates 2D image data of the lung during a plurality of breathing cycles. A computer is programmed and operable to group the 2D image data into subsets based on their point (or optionally phase) in the breathing cycle, and to reconstruct the 2D image data subsets into a 3D image volume based on the location information of the probe. Optionally, the 3D reconstructed image volume is displayed with target and route information. In embodiments, the computer is further operable to detect and track a surgical device in the lung such as an aspiration needle and to display the surgical device in the 3D reconstructed image volume for assisting the physician reach the target. Related methods are also described.
Participants will receive the RP2D of mirdametinib. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of AVONEX cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice. 

Among 351 patients with relapsing forms of MS treated with AVONEX 30 micrograms (including 319 patients treated for 6 months and 288 patients treated for greater than one year) the most commonly reported adverse reactions (at least 5% more frequent on AVONEX than on placebo) were flu-like symptoms. Symptoms can include chills, fever, myalgia and asthenia occurring within hours to days following an injection. Most people who take AVONEX have flu-like symptoms early during the course of therapy. Usually, these symptoms last for a day after the injection. For many people, these symptoms lessen or go away over time. The most frequently reported adverse reactions resulting in clinical intervention (for example, discontinuation of AVONEX or the need for concomitant medication to treat an adverse reaction symptom) were flu-like symptoms and depression. 

Table 2 enumerates adverse reactions that occurred with AVONEX-treated patients at an incidence of at least 2% more than that observed in the placebo-treated patients in the pooled placebo-controlled studies in patients with relapsing forms of MS [see Clinical Studies (14)]. 

Immunogenicity

Anaphylaxis and other allergic reactions have occurred in AVONEX-treated patients [see Warnings and Precautions (5.3)]. As with all therapeutic proteins, there is a potential for immunogenicity. In studies assessing immunogenicity in multiple sclerosis patients administered AVONEX for at least 1 year, 5% (21 of 390 patients) showed the presence of neutralizing antibodies at one or more times. 

These data reflect the percentage of patients whose test results were considered positive for antibodies to AVONEX using a two-tiered assay (ELISA binding assay followed by an antiviral cytopathic effect assay), and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of neutralizing activity in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to AVONEX with the incidence of antibodies to other products may be misleading.
Although the energy stored in lean tissue (LT) and adipose tissue (AT) is well known, the energy required to synthesize these tissues is less clear. While elucidating the energy required for AT synthesis may not be so important, the elucidation of the energy required for LT synthesis is important for individuals who aim to increase their skeletal muscle. Theoretically the energy at the point at which ΔLT/Δbody weight (BW) reaches 100% on a regression curve, which indicates the relationship between ΔLT/ΔBW and the energy used to accumulate body tissue, is considered to be the energy expended to synthesize LT. We therefore investigated the relationship using rats. Rats of different ages, and rats in exercised or sedentary states were used because their ΔLT/ΔBW was expected to be different. ΔLT/ΔBW was higher in the 4-wk-old group than in the 8-wk-old group and higher in the exercise group than in the sedentary group. We found a positive correlation between ΔLT/ΔBW and the energy expended to synthesize tissues that accumulated in the body. This energy was lower in the 8-wk-old group, which had a lower ΔLT/ΔBW in comparison to the 4-wk-old group, but was not affected by exercise. The regression curve revealed that the energy expended to synthesize LT was 2.9 kcal/g, while that expended to synthesize AT was 1.1 kcal/g. Therefore, combined with the energy accumulated to the tissues, the energy required to accumulate LT is approximately 4.0 kcal/g, while that required to accumulate AT is approximately 8.5 kcal/g.
PURPOSE: A pharmaceutical composition containing Ulmus davidiana var. japonica extract with antasthmatic activity is provided to health food or health supplementary food. CONSTITUTION: A pharmaceutical composition for preventing or treating asthma contains Ulmus davidiana var. japonica extract as an active ingredient, isolated by water, alcohol, or mixture thereof. The alcohol is ethanol or methanol. A health food for preventing or treating asthma contains Ulmus davidiana var. japonica extract as an active ingredient.
INTRODUCTION: Acute respiratory distress syndrome (ARDS) is defined in critically ill patients with acute hypoxemia and positive-pressure ventilation in association with several clinical disorders including trauma, pneumonia, sepsis, and aspiration. The prone position has been used for many years and is now recommended for patients with severe or moderate-to-severe ARDS on invasive mechanical ventilation. Acute kidney injury (AKI) is a common complication in patients with ARDS, with up to a 35% incidence rate. Initiation of Kidney Replacement Therapy (KRT) requires wise clinical judgment and collaboration between nephrologists and intensivists. A properly functioning vascular access is critical for an optimized KRT. Our institute is a national referral center for respiratory diseases.
RESULTS: We describe 11 cases of dialysis catheter placement for KRT in critically ill patients with ARDS on mechanical ventilation in prone position. The catheter was placed in the first puncture attempt in nine cases, Blood flows (Qb) achieved were 283.4 ± 20.4 ml/min during the session, in six cases the radiologic tip location was achieved in the peri cavoatrial junction; in four cases was achieved in mid to- deep right atrium. The dialysis quality standards were based on KTV and in URR; in nine cases (81.81%) KTV was in 1.3 and in all cases (100%) URR was >65%, lumen dysfunction was reported only in two cases (18.1%), but these cases did respond to mobilization maneuvers. The procedure time of placement was 29.8 min, no arterial punctures or complications were reported.
CONCLUSIONS: We demonstrate that in our study hemodialysis non-tunneled catheter placement in the prone position is safe and effective. We believe this practice could be frequently used in the near future and represent an opportunity window for the training of interventional nephrologists and related areas.
Participants in the experimental group receive both RIC and standard clinical therapy. The RIC treatment is composed of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 180 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion (Patent No.CN200820123637.X, China).
It consists of 12 sessions, each lasting 75 minutes for each children. Parallel parents will participate in the parental guidance and psychoeducation program with one of the two therapists assigned to the child.
PURPOSE: To obtain the subject new compound, having low irritancy to the skin or hair, good in tough thereon, excellent in foaming power and emulsification stability and useful for various detergents, emulsifying agents, conditioning agents, etc. CONSTITUTION: A multichain type amine derivative of formula I [R<1> is a (hydroxyl-substituted)straight-chain or branched chain 1-24C alkyl or alkenyl; R<2> is a (hydroxyl-substituted)straight-chain or branched chain 1-4C alkyl or alkenyl; X is a halogen], e.g. tris(2-hydroxy-4,4-dimethyl-4-azoniadodecyl)amine chloride. The compound of formula I is obtained by reacting an amine derivative of formula II with one or two or more halogenated hydrocarbons having different R<2> groups of the formula R<2> -X. Furthermore, the reaction is preferably carried out by reacting the compound of formula II with the halogenated hydrocarbon in an equiv. amount of 2-10 times based on three amino groups in the compound of formula II in the presence of, e.g. an inert solvent at 20-150 deg.C, preferably 60-120 deg.C.
This study, conducted in June and July 2022 through purposive sampling, aimed to explore the relationship between sleep and health performance in 33 pairs of elderly individuals and their migrant caregivers in southern Taiwan. Participants completed a structured questionnaire and wore an Actiwatch for seven days. Pearson correlation and independent t-test were used for analysis. Nearly 50% of foreign home care workers suffered from insomnia, and 80% of elderly care recipients with disabilities experienced sleep disorders. The number of chronic illnesses and/or dementia among the elderly and insomnia among care workers were associated with poor self-perceived health (r = -0.667, p < .001) and sleep disorders among the elderly (r = 0.368, p = .035). The problem of caregiving should be addressed. Future studies should increase the sample size and extend the duration of the study to enhance the generalizability of the findings.
Risk Summary

There are limited and incomplete human data from clinical trials and postmarketing reports on use of KALYDECO in pregnant women. In animal reproduction studies, oral administration of ivacaftor to pregnant rats and rabbits during organogenesis demonstrated no teratogenicity or adverse effects on fetal development at doses that produced maternal exposures up to approximately 5 (rats) and 11 (rabbits) times the exposure at the maximum recommended human dose (MRHD). No adverse developmental effects were observed after oral administration of ivacaftor to pregnant rats from organogenesis through lactation at doses that produced maternal exposures approximately 3 times the exposures at the MRHD, respectively (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and miscarriage is 15% to 20% in clinically recognized pregnancies.

Data

Animal Data

In an embryo-fetal development study in pregnant rats dosed during the period of organogenesis from gestation days 7-17, ivacaftor was not teratogenic and did not affect fetal survival at exposures up to 5 times the MRHD (based on summed AUCs for ivacaftor and its metabolites at maternal oral doses up to 200 mg/kg/day). In an embryo-fetal development study in pregnant rabbits dosed during the period of organogenesis from gestation days 7-19, ivacaftor was not teratogenic and did not affect fetal development or survival at exposures up to 11 times the MRHD (on an ivacaftor AUC basis at maternal oral doses up to 100 mg/kg/day). In a pre- and post-natal development study in pregnant female rats dosed from gestation day 7 through lactation day 20, ivacaftor had no effects on delivery or growth and development of offspring at exposures up to 3 times the MRHD (based on summed AUCs for ivacaftor and its metabolites at maternal oral doses up to 100 mg/kg/day). Decreased fetal body weights were observed at a maternally toxic dose that produced exposures 5 times the MRHD (based on summed AUCs for ivacaftor and its metabolites at a maternal oral dose of 200 mg/kg/day). Placental transfer of ivacaftor was observed in pregnant rats and rabbits.
Healthy controls will be recruited from the general population and will be matched based on age, sex, and BMI. They will be assess at two time points, 48 hours apart. At each testing day, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity.
Stridor is a symptom of upper airway obstruction and may result from congenital or acquired causes. The diagnosis is usually clinical. If further investigation is necessary for differential diagnosis, endoscopy is the method of choice in most cases. Imaging studies are complementary to endoscopy. They allow evaluation of laryngeal and tracheobronchial pathology and extrinsic airway compressions due to tumors or vascular malformations and define a lesion's location, extent, and characteristics. They are helpful in cases of diagnostic doubt and when endoscopy is unavailable. It is essential to understand the anatomy and pathophysiology of the respiratory tract and to be aware of the indications and limitations of complementary examinations for proper diagnosis. The different imaging modalities available to evaluate stridor in pediatrics are described, and their advantages are discussed.
Congenital ventricular aneurysms (CVA) are rare cardiac anomalies that have been predominantly described in the Black population. They are characterized by an akinetic ventricular protrusion that is commonly located at the basal and apical segments. Although the diagnosis is often incidental and the majority of patients are asymptomatic, life-threatening events such as persistent ventricular arrhythmias, CVA rupture, and heart failure are not uncommon. However, no standardized therapy is currently available and good outcomes have been reported with both conservative and surgical management. We report the cases of two young Black African patients with huge symptomatic CVA lesions who underwent successful surgical repair with a ventricular restoration technique. Both cases were consulted for chest pain and dyspnea. Chest X-ray and transthoracic Doppler echocardiography suggested the diagnosis. Thoracic angioscanner and thoracic magnetic resonance imaging confirmed the diagnosis. Both patients underwent successful surgery. This case report aims to revisit the diagnostic and therapeutic approach to this rare pathology, in our professional environment.
The study was designed prospectively. A total of 50 patients with subacromial impingement syndrome according to clinical and MRI findings with shoulder pain for at least 3 months were included in the study. Patients were randomly divided into two groups. The first group (isokinetic exercise group, n = 25) was given isokinetic exercise. The second group(home exercise group, n=25) was given home exercise program. Patients were evaluated before and after treatment and 3 months after the end of treatment. In the evaluation, VAS, Shoulder Pain and Disability Index, Constant Murley Scoring, Shoulder Disability Questionnaire, Health Assessment Questionnaire, Pittsburgh Sleep Quality Index, Humic Norm II isokinetic device were used. At statistically evaluation of data Student T Test and Mann Whitney U tests were used. In qualitative datas comparison Ki-Kare Test was used. Significance was evaluated at the level of p\< 0.05.
Background ：The elderly are a high-risk group for developing frailty symptoms. The prevalence of frailty ranges from 16% for those over 65 years of age to 52% for those over 85 years of age, and it increases proportionally with age. Frailty is not a disease. It represents the cumulative functional degeneration of various systems. It is a sub-healthy state or a stage before disability. Some elderly people have different degrees of frailty. In mild cases, there may be no clinical symptoms. Interference part of life; more severe cases may lead to disability or disease.

Objective：This study first explored the relationship between basic demographic variables, frailty and health function of community-based adults and elderly. Promote and explore the effect of the Frailty Prevention Care Management Program (FPCMP-Old Age) on the frailty and health function of the elderly in the community.

Methods：The elderly in the long-term care community bases in the central and southern regions were selected as the object of acceptance. The study design is divided into two years(Two phases) study, the first phase is to develop a 12-week frailty prevention care management plan (FPCMP-Old Age). The second stage is to introduce FPCMP-Old Age to carry out a pilot study in the south-central community. A total of 70 cases were accepted in the experimental group and the control group. This study was divided into two groups, which were grouped by convenient sampling. The experimental group underwent the FPCMP-Old Ag program; the control group only maintained the original site to delay disability and dementia activities. In this study, pre-intervention, post-intervention, and four-week follow-up were conducted, and three questionnaires were evaluated. Each time it was estimated to spend 30 minutes for each answer, the activity lasted for 12 weeks. The execution period this time is from January 1, 2023 to December 30, 2024, but the time for accepting cases is from June 1, 2023 to December 31, 2023. There are four research tools in this study, namely: demographic variables, chronic disease and health problem scale, frailty detection tool (TFI-T), health function (refer to the 2016 recommendation of the Ministry of Education and Sports Administration for the fitness of the elderly group Test items, testing the subject's body composition, upper and lower limb muscle strength, upper and lower limb flexibility, cardiorespiratory endurance, dynamic and static balance) and nutritional status (mini nutritional assessment) and other tools. Data were collected in triplicate, and generalized estimating equations were used to analyze whether there were differences in interaction effects between groups, within groups, and time.

Conclusions/practical application： The Frailty Prevention Care Management Program (FPCMP-Old Age) can help community-based adults and older adults reduce frailty and improve health function.